NCT06588257View on ClinicalTrials.gov

Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

April 9, 2026

Study Completion Date

April 9, 2026

Conditions
HPV
Interventions
BIOLOGICAL

Non-infectious adjuvanted recombinant nonavalent HPV vaccine

Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).

Trial Locations (1)

C1427CEA

Fundación Huésped, Ciudad Autónoma de Buenos Aires

Sponsors

Collaborators (1)

MSD Pharmaceuticals LLC
All Listed Sponsors
collaborator

MSD Pharmaceuticals LLC

INDUSTRY

lead

Fundación Huésped

OTHER

NCT06588257 - Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study | Biotech Hunter | Biotech Hunter